Evidence mapPaperPMID 40528138Full record

ReviewReviews in endocrine & metabolic disorders2025

Exploring obesity phenotypes: a longitudinal perspective.

Ricardo Rosero-Revelo, Mateo Tamayo, Ricardo Correa, Kevin M Pantalone, David Creel, Bartolome Burguera, Marcio L Griebeler

Abstract readReview
In one paragraph

Review in Reviews in endocrine & metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ricardo Rosero-ReveloDepartment of Endocrinology, Diabetes and Metabolism, Cleveland Clinic, Cleveland, OH, USA. roseror@ccf.org.ORCID 0000-0003-4384-8629
Mateo TamayoObesity Center, Fundación Santa Fe de Bogotá University Hospital, Bogotá D.C, Colombia.ORCID 0009-0007-9764-3203
Ricardo CorreaDepartment of Endocrinology, Diabetes and Metabolism, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0003-2761-2907
Kevin M PantaloneDepartment of Endocrinology, Diabetes and Metabolism, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0002-3897-4551
David CreelDepartment of Endocrinology, Diabetes and Metabolism, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0003-0521-0173
Bartolome BurgueraDepartment of Endocrinology, Diabetes and Metabolism, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0001-9808-8327
Marcio L GriebelerDepartment of Endocrinology, Diabetes and Metabolism, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0001-5723-1182

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Traditional reliance on Body Mass Index (BMI) as a diagnostic tool for obesity is increasingly challenged due to its inability to differentiate between fat and lean mass and to capture fat distribution. Emerging evidence-including findings from our longitudinal study in Latino patients with obesity and insights from the 2025 Lancet Commission on Obesity-suggests that a comprehensive evaluation of body composition is essential for accurate risk stratification. This review synthesizes historical perspectives and recent developments in obesity phenotyping, detailing how the field has evolved from simple BMI-based assessments to multifaceted approaches incorporating bioelectrical impedance analysis (BIA) and supplementary anthropometric measures such as waist circumference and waist-to-hip ratio. We also examine the metabolic, genetic, and hormonal mechanisms underlying phenotypic variability, which help explain why individuals with similar BMIs may exhibit markedly different health risks. By integrating our original data with an extensive review of current literature, we demonstrate that refined obesity phenotyping can serve as an early indicator of progression from preclinical to clinical obesity. Such nuanced classifications offer the potential for more personalized therapeutic interventions aimed at optimizing weight loss outcomes and reducing cardiometabolic risk. Overall, our findings advocate for a multidimensional approach to obesity assessment that promises to improve clinical outcomes through tailored, phenotype-based strategies.

Indexed as

Body CompositionObesityBody Mass IndexHumansLongitudinal StudiesPhenotype

Identifiers

PMID40528138
PMCPMC12602548

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.